

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

June 2021

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, uppercase, sans-serif font below it. The logo is centered within a white circle.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 June 2021	3
Section H changes to Part II	4
Index	5

Summary of decisions

EFFECTIVE 1 JUNE 2021

- Ciprofloxacin (Ciprofloxacin Teva) eye drops 0.3%, 5 ml – price decrease and addition PSS
- Diclofenac (Voltaren Ophtha) eye drops 0.1%, 5 ml – price decrease and addition of PSS
- Disulfiram (Antabuse) tab 200 mg – price decrease and addition of PSS
- Factor Eight Inhibitor Bypassing Fraction (FEIBA NF) inj 500 U – Pharmacode change
- Hydrocortisone (Solu-Cortef) inj 100 mg vial – price decrease and addition of PSS
- Lidocaine [Lignocaine] hydrochloride (Lidocaine-Baxter) inj 1%, 5 ml ampoule – new listing
- Lidocaine [Lignocaine] hydrochloride (Lidocaine-Claris) inj 1%, 5 ml ampoule – to be delisted 1 January 2022
- Multiple sclerosis treatments – amended restriction criteria
- Oxybutynin (Apo-Oxybutynin) tab 5 mg and oral liq 5 mg per 5 ml – restriction added
- Paracetamol (Noumed Paracetamol) tab 500 mg – bottle pack – new listing and addition of HSS

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 June 2021

BLOOD AND BLOOD FORMING ORGANS

30	FACTOR EIGHT INHIBITOR BYPASSING FRACTION – Restricted (Pharmacode change) → Inj 500 U	1,315.00	1	FEIBA NF
Note – this is a new Pharmacode listing, 2583992. Pharmacode 2388790 to be delisted 1 November 2021.				

GENITO-URINARY SYSTEM

63	OXYBUTYNIN – Restriction: For continuation only (restriction added)			
	Tab 5 mg.....	11.70	500	Apo-Oxybutynin
	Oral liq 5 mg per 5 ml	60.40	473 ml	Apo-Oxybutynin

HORMONE PREPARATIONS

66	HYDROCORTISONE (↓ price and addition of PSS) Inj 100 mg vial – 5% DV Nov-21 to 2024	4.38	1	Solu-Cortef
----	---	------	---	--------------------

NERVOUS SYSTEM

109	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (brand change) Inj 1%, 5 ml ampoule.....	8.75	25	Lidocaine-Baxter
Note – Lidocaine-Clarix inj 1% to be delisted 1 January 2022.				
111	PARACETAMOL (new listing and addition of HSS) Tab 500 mg – bottle pack – 1% DV Dec-21 to 2024	17.92	1,000	Noumed Paracetamol
123	MULTIPLE SCLEROSIS TREATMENTS (restriction criteria amended – affected criteria shown only) Continuation — Multiple sclerosis Neurologist or general physician Patient has had an EDSS score of 0 to 6.0 (inclusive) with or without the use of unilateral or bilateral aids at any time in the last six months (i.e. the patient has walked 100 metres or more with or without aids in the last six months)			
128	DISULFIRAM (↓ price and addition of PSS) Tab 200 mg – 5% DV Nov-21 to 2024	236.40	100	Antabuse

SENSORY ORGANS

215	CIPROFLOXACIN (↓ price and addition of PSS) Eye drops 0.3% – 5% DV Nov-21 to 2024	9.73	5 ml	Ciprofloxacin Teva
217	DICLOFENAC SODIUM (↓ price and addition of PSS) Eye drops 0.1% – 5% DV Nov-21 to 2024	8.80	5 ml	Voltaren Ophtha

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

Index

Pharmaceuticals and brands

A

Antabuse 4

Apo-Oxybutynin 4

C

Ciprofloxacin 4

Ciprofloxacin Teva..... 4

D

Diclofenac sodium 4

Disulfiram 4

F

Factor eight inhibitor bypassing fraction..... 4

FEIBA NF..... 4

H

Hydrocortisone 4

L

Lidocaine-Baxter 4

Lidocaine [Lignocaine] hydrochloride 4

Lignocaine 4

M

Multiple sclerosis treatments 4

N

Noumed Paracetamol..... 4

O

Oxybutynin..... 4

P

Paracetamol..... 4

S

Solu-Cortef 4

V

Voltaren Ophtha 4

New Zealand
Permit No. 478



Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1172-3694 (Print)

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa [New Zealand Government](#)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand